The use of mitoxantrone and melphalan prior to stem cell transplantation in multiple myeloma patients results in favorable survival rates and manageable side effects, according to the results of a Phase 2 clinical trial.

Although the results of the study are encouraging and confirm the results of previous trials, Dr. Anne Beaven, from Duke University Medical Center and lead author of the study, noted that the trial was conducted before the introduction of novel agents into routine clinical practice.

“Until a trial is performed combining this regimen with maintenance Revlimid (lenalidomide) …